PATENT/ Attorney Docket No.: 15270J-004760US Client Reference No.: 209-US-CIP8B

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office, Technical Center 1600:

Fax No. 1-703-872-9306

on 166.18,2003

TOWNSEND and TOWNSEND and CREW LLP

Rosemeria I. Calli

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Dale B. Schenk et al.

Application No.: 09/580,018

Filed: May 26, 2000

For: PREVENTION AND TREATMENT

OF AMYLOIDOGENIC DISEASE

Examiner:

Turner, Sharon

Art Unit:

1647

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37

CFR §1.97 and §1.98

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

The references cited on attached PTO/SB/08A and PTO/SB/08B forms are being called to the attention of the Examiner. In accordance with 37 CFR § 1.98(d) copies of citation numbers 220-304 can be found in Application No. 09/322,289 filed May 28, 1999 (Attorney) Docket No. 15270J-004740US): copies of reference citation nos. 305-309 can be found in Application No. 09/201,430 filed November 30, 1998 (Attorney Docket No. 15270J-004720US). It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

"Grant Application; Raso, Immunology of Alzheimer's Disease', 1/1998," cited by the Examiner in Application No. 09/579,690, is submitted herewith as cite no. 304.

Dale B. Schenk et al. Application No.: 09/580,018

Application No. 09/579,690 is a commonly owned copending application directed to subject matter related to the instant application. Applicants believe "1/1998" is not the publication date as alleged by the Examiner, but refers to the grant funding cycle. Applicants further believe the date of public accessibility, if any, is unknown. Applicants wish to bring to the Examiner's attention that a copy of a grant application believed to have been submitted by Victor Raso for NIH Grant 1 R43 AGI 5746-01 on August 29, 1997 was previously submitted in the Supplemental IDS submitted October 18, 2001 as cite no. 144. Cite no. 144 is a redacted version of cite no. 304. Applicants obtained cite no. 144 under the Freedom of Information Act (FOIA). It is believed that the grant proposal would not have been accessible under FOIA before April 2, 1998, but the exact date of public accessibility, if any, is not known to Applicants."

The Assignee of the instant application is a licensee of U.S. Patent No. 5,688,651, which is directed in part to subject matter related to the instant application. U.S. Patent No. 5,688,651 is now undergoing examination reissue as Application No. 09/441,140. U.S. Application No. 09/441,140 is submitted herewith as cite number 283. U.S. Patent No. 7 \*\* 5,688,651 was previously submitted in the Initial IDS submitted October 30, 2000 as cite no. AO.

Applicant also cites commonly owned copending applications directed to related subject matter:

> 09/201,430 filed 11/30/98; 09/497,553 filed 02/03/00; 09/724,477 filed 11/28/00; 09/723,927 filed T1/28/00; 09/724,762 filed 11/28/00;-09/724,102 filed 11/28/00; 09/724,489 filed 11/28/00; 09/322,289 filed-05/28/99; 09/723,713 filed 11/27/00; 09/723,760 filed 1·1/27/00; 09/724,319 filed 11/27/00; 09/723,384 filed 11/27/00;

W.

Dale B. Schenk et al.

Application No.: 09/580,018

09/724,495 filed 11/27/00; 09/580,015 filed 05/26/00; \_\_\_\_ 09/724,940 filed 11/28/00; 09/724,961-filed 11/28/00; @ 09/580,018 filed 05/26/00; 09/724,552 filed 11/28/00;

09/723,544 filed 11/28/00;

09/724,273 filed 11/28/00;

09/724,551 filed 11/28/00;

09/724,288 filed 11/28/00;

09/580,019 filed 05/26/00;

09/723,765 filed 11/28/00;

09/724,291 filed 11/28/00;

09/204,838 filed 12/03/98;

09/724,921 filed-11/28/00;

09/724,929 filed 11/28/00;

09/585,817 filed 06/01/00;

09/724,567 filed 11/28/00;

09/724,575 filed 11/28/00;

09/724,953 filed 11/28/00;

\_09/724,570 filed 11/28/00;

09/585,656 filed 06/01/00;

09/723,766 filed 11/27/00;

09/723,725 filed 11/27/00;

09/579,690 filed 05/26/00;

09/979,701 filed 03/13/01 (U.S. National Stage of PCT/US00/14810 filed

05/26/00);

09/979,952-filed 04/04/02 (U.S. National Stage of PCT/US00/15239 filed

06/01/00); and, ....

PATENT

Dale B. Schenk et al. Application No.: 09/580,018 Page 4

09/980,568 filed 03/12/02 (U.S. National Stage of PCT/US00/15302 filed

06/01/00).

Applicant also cites the following copending application directed to related subject matter but subject to different assignment:

10/010,942 filed 12/06/01; and,

10/232,030 filed 08/30/02.

Applicant further cites the following commonly owned abandoned applications directed to related subject matter:

60/067,740 filed 12/02/97;

60/080,970 filed 04/07/98;

60/067,219 filed 12/03/97;

60/079,697 filed 03/27/98;

60/137,010 filed 06/01/99;

60/137,047 filed 06/01/99; and,

60/136,655 filed 05/28/99.

Applicant also cites the following abandoned application directed to related subject matter but subject to different assignment:

60/251,892 filed 12/06/00.

Applicant points out that the following applications are now commonly assigned but were previously subject to different assignment than the present application:

60/067,219 filed 12/03/97;

60/079,697 filed 03/27/98;

09/204,838 filed 12/03/98;

09/724,921 filed 11/28/00; and;

09/724,929 filed 11/28/00.

As provided for by 37 CFR 1.97(g) and (h), no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information, and no inference should be made that the information and references cited are of are considered to be material to patentability because they are in this statement. No inference

Dale B. Schenk et al. Application No.: 09/580,018

Page 5

should be made that the information and references cited are prior art merely because they are in this statement.

Applicant believes that no fee is required for submission of this statement, since it is being submitted prior to the first substantive Office-Action. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

Rosemarie L. Celli Reg. No. 42,397

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, 8<sup>th</sup> Floor San Francisco, California 94111-3834 Tel: 650-326-2400 Fax: 650-326-2422 RLC

PA 3242969 v1